(marketscreener.com) DUBLIN, July 13, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that Zepzelca was added by the National Comprehensive Cancer Network to the Clinical Practice Guidelines in Oncology for small cell lung cancer on July 7, 2020. The U.S. Food and Drug Administration approved Zepzelca under accelerated approval on...https://www.marketscreener.com/JAZZ-PHARMACEUTICALS-PLC-9829261/news/Jazz-Pharmaceuticals-National-Comprehensive-Cancer-Network-adds-Zepzelca-trade-lurbinectedin-t-30915702/?utm_medium=RSS&utm_content=20200713
